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Analyses of the human genome have proven extremely successful in identifying changes that
contribute to human disease. Genetically engineered mice provide a powerful tool to analyze these
changes, although they are slow and costly and do not always recapitulate human biology. Recent
advances in genomic technologies, rodent-modeling approaches, and the production of patient-
derived reprogrammed cell lines now provide a plethora of complementary systems to study
disease states and test new therapies. Continued evolution and integration of thesemodel systems
will be the key to realizing the benefits of the genomic revolution and refining our understanding and
treatment of human diseases.Introduction
There is no broader topic in mammalian genetic research than
human disease. Literally thousands of human diseases, disor-
ders, and syndromes have been described and, through
advances in genome technologies, are being characterized in
much greater molecular detail. The fundamental challenge for
medical research is to develop and exploit the most relevant
and predictive model systems to understand the physiological
impact of this genetic variation, with the ultimate goal of
improving patient care and treatment. Already in the past two
decades, the range of approaches used to study gene function
in normal and diseased states has increased dramatically.
However, as our depth of knowledge has grown so too have
our expectations—both in the accuracy of experimental models
to recapitulate human conditions as well as in the speed and
scope at which they can be applied to ask biological questions.
These expectations are now being met through new
approaches that integrate existing models systems with power-
ful new genetic technologies, thereby changing the scale and
depth at which we can understand the genetics of disease.
Although many effective model systems exist, we focus our
discussion predominantly on the laboratory mouse and new
technologies and approaches in mouse genetics that will have
a major impact on disease research in the next 10 years. In addi-
tion, we highlight efforts to translate advances in modeling
disease in mice to other mammalian systems and the develop-
ment of the next generation of rodent and human genetic
models. Combined, these efforts will ensure that biologists
keep pace with the flood of information arising from genomic
data and lead to quantum leaps in our understanding of disease
and the development of new therapeutic strategies.
The Powerhouse Mouse
For more than 100 years, the laboratory mouse (Mus musculus)
has served as the backbone of mammalian genetic research.Mice are small, inexpensive to house, breed quickly, are
amenable to genetic manipulation, and, importantly, share
almost 99% of their genes with humans. To disease research,
the mouse serves as both an investigative tool—defining the
role of individual genes in disease manifestation and progres-
sion—and a discovery tool—allowing the identification of previ-
ously uncharacterized genes and molecular interactions that
underlie disease states.
Step-wise advances in mouse embryonic stem cell (ESC)
culture and homologous recombination-mediated targeting
over the past 20 years have led to the creation of an extensive
toolkit with which to manipulate the mouse genome (Figure 1).
Through the adaptation of regulated promoters and DNA recom-
binase systems (Flp/FRT and Cre/LoxP), it is now possible to
constitutively or inducibly mutate or delete (knockout) individual
genes or large genomic regions in a temporal and cell-type-
dependent manner (reviewed in Frese and Tuveson, 2007).
Deletion of many thousands of genes in mice by this approach
has been critical for the functional annotation of genes in normal
and disease states and established model systems for preclin-
ical treatment studies.
However powerful, the process to generate a knockout or
conditional knockout/mutant mouse is slow and expensive. It
has been estimated that the development of a single targeted
knockout mouse can cost $30,000–$100,000 and take up to
1 year to complete—many months longer if the resulting allele
needs to be recombined in vivo or backcrossed to a specific
strain (Figure 2). It is not only the time and cost that is restrictive.
Unlike ‘‘lower’’ genetic model systems such as the worm and fly,
the labor associated with production of genetically engineered
mice (GEM) usually limits the development of new models
to only a handful of genes/lab/year, if any at all. In stark
contrast, the accessibility of genome-wide analysis tools (micro-
array, ChIPseq, CGH), large-scale genome-wide association
studies (GWAS), and mutagenesis and complex library screensCell 148, March 16, 2012 ª2012 Elsevier Inc. 1099
Figure 1. New Tools in Mammalian Disease Models
Platforms for the geneticmanipulation of mammalianmodel systems (primarily
mouse, rat, and human) have developed at an incredible rate in the past 10–15
years. Recent sophisticated adaptations in each of these systems (indicated in
yellow) now provide an extremely flexible array of tools for investigating and
understanding the underlying causes of human disease.(discussed later) have produced hundreds if not thousands of
potential disease-associated genes that need to be thoroughly
vetted in animal models. Thus, despite the impact genetically en-
gineeredmice have had on our understanding of human disease,
traditional methods lack the speed and scale to handle the
onslaught of information arising from genomic studies. Nonethe-
less, considerable steps are being taken to address the need for
faster and more scalable approaches to make mouse models
a force in the post-genomics future.
Stop-and-Shop Mouse Models
A major bottleneck in the development of targeted genetic
models is the painstaking, one-by-one production of specific
gene-targeting vectors. For the production of knockout mice
(constitutive and conditional), this is largely a thing of the past.
Both commercial entities and large publicly funded consortia
have made significant progress in establishing extensive repos-1100 Cell 148, March 16, 2012 ª2012 Elsevier Inc.itories of gene-targeting vectors as well as pretargeted ESCs
and GEM. The MICER repository (http://www.sanger.ac.uk/
resources/mouse/micer) offers thousands of ready-made tar-
geting vectors for generating both constitutive and conditional
alleles (Adams et al., 2004). In addition, because MICER
provides vectors for targeting thousands of regions throughout
the genome, it offers a shortcut formanipulation of large chromo-
somal regions through chromosome engineering. International,
multi-institute initiatives such as the International Knockout
Mouse Consortium (IKMC) (http://www.knockoutmouse.org),
incorporating the Knockout Mouse Project (KOMP: http://
www.nih.gov/science/models/mouse/knockout/) and the
EuropeanConditionalMouseMutagenesis program (EUCOMM),
as well as the Gene Trap consortium (http://www.genetrap.org),
provide vectors as well as pre-engineered ESC lines. As of
February 2012, the IKCM had amassed close to 18,000 deletion,
conditional deletion, and gene trap alleles in ESCs, and it is
expected that targeting of the majority of the mouse genes and
microRNAs (miRNAs) will be completed within a few years
(Skarnes et al., 2011). A major part of this effort has been spear-
headed by members of the Wellcome Trust Sanger Institute
(William Skarnes and Alan Bradley), who use an elegant
‘‘knockout first’’ targeting strategy that, from a single targeting
event, allows the creation of transcriptional reporter (gene
trap), conditional, and constitutive deletions in ESCs and/or
mice (Skarnes et al., 2011). Together, the targeting vector and
ESC repositories provide a much-needed resource for the
medical research community and will significantly decrease the
time associated with the future development of knockout strains.
In addition, large-scale and systematic phenotyping efforts (e.g.,
International Mouse Phenotyping Consortium: http://www.
mousephenotype.org/) will provide investigators with much
needed baseline information as they begin to explore the biology
of poorly characterized genes.
New methods have also been developed to accelerate the
process of transgene delivery in mammalian cells. Recombi-
nase-mediated cassette exchange (RMCE), pioneered by Juer-
gen Bode and colleagues (Seibler et al., 1998), is a particularly
efficient means to target transgenes to a defined genomic region
and avoid the consequences of positional effects on transgene
expression. This strategy has been used to derive robust ESC
lines carrying RMCE ‘‘acceptor sites’’ at the Rosa26 and
Col1A1 loci (Hitz et al., 2007; Hochedlinger et al., 2005; Seibler
et al., 2007), and efforts are underway to identify additional
‘‘safe-harbor’’ loci in the mouse that are immune to epigenetic
silencing. RMCE-ready ESC lines enable the simple and reliable
production of transgenic mice on a new scale. Using ColA1-
RMCE (KH2) ESCs developed by the Jaenisch laboratory and
our recently described shRNA-targeting platform (Premsrirut
et al., 2011), we are now developing an NCI-funded, public
repository of 1,500 ESC lines carrying doxycycline-inducible
miRNAs that can be used to study miRNA biology in ESCs or
mice (Y. Park, G. Hannon, and S.W.L., unpublished data).
Exploiting RNA Interference
RNA interference (RNAi) is an extremely powerful method of
gene regulation that is conserved throughout evolution. Initially
most effective for studying gene function in model organisms
such as C. elegans and Drosophila, it is now established that
RNAi can also be achieved in mice through the transgenic
expression of short hairpin RNAs (shRNAs), offering an effective
alternative to the traditional knockout approach. shRNAs, ex-
pressed as stem-loop RNAs or embeddedwithin an endogenous
miRNA fold, induce targeted gene silencing by stably reducing
mRNA transcript levels and/or inhibiting translation. Although
they do not induce complete gene loss, the key feature of
shRNAs that makes them so powerful for in vivo studies is that
they function in trans; hence, whereas traditional knockouts
require deletion of both gene copies, a single shRNA allele can
induce silencing of a gene (or genes) expressed from two alleles.
The reduced need for allelic intercrossing enables faster gener-
ation of models systems for analysis.
Because shRNAs do not disrupt the endogenous locus of the
target gene, their silencing effects are reversible, so the require-
ment for gene function can be investigated during defined inter-
vals of normal development or disease pathogenesis. Such
reversible approaches facilitate evaluation of the consequences
of inhibiting a putative drug target on disease progression, where
transient target suppression in established disease may accu-
rately mimic the impact of a drug treatment. By contrast,
achieving similar capabilities with standard genomic engineering
is tedious and requires dedicated allelic variants (Ventura et al.,
2007).
Our lab and others have taken advantage of the efficiency of
RMCE targeting in combination with shRNA technology to
produce a fast and scalable platform that allows production of
mice with tissue-specific, inducible, and reversible gene
silencing (Dow et al., 2012). As the production and targeting of
shRNA cassettes are standardized and efficient, it is reasonable
to envisage the creation of a genome-wide repository of ESC
lines carrying shRNAs targeting the mouse genome. Although
such a collection does not yet exist, the recent development of
a high-throughput functional assay for identification of potent
shRNAs (Fellmann et al., 2011) will inevitably lead to the produc-
tion of genome-wide prevalidated shRNA libraries that can be
quickly adapted for generation of transgenic mice.
Genome Editing in a Flash
Many disease-associated genetic changes involve point muta-
tions, and large sequencing efforts are identifying ever more
single-nucleotide variations of potential disease relevance.
Such changes may produce loss of function (akin to knockouts)
but may also induce gain of function or altered gene function,
and many may be found outside protein-coding regions (see,
for example, Bond et al., 2004). With knockout production
moving forward at a rapid pace, how will the production of
disease-relevant point mutations be systematically addressed?
Unfortunately there is currently no coordinated effort to produce,
en masse, conditional ‘‘endogenous’’ mutant alleles like LSL-
Trp53R270H or LSL-KrasG12D (Jackson et al., 2001; Olive et al.,
2004). However, new technologies developed and tested for
gene disruption and homologous recombination in rat and
human cells could prove an invaluable tool for the rapid genera-
tion of targeted point mutations in mice. Zinc finger nucleases
(ZFNs) and TAL effector nucleases (TALENs) are, in effect,
genomic scissors—recombinant, sequence-specific DNA nucle-
ases that can be adapted to recognize specific nucleotide
sequences and induce DNA breaks. These double-strandbreaks, through homologous repair from exogenous template
DNA, can be directed to incorporate anything from a single
nucleotide change to a large transgenic insertion (for review,
see Bogdanove and Voytas, 2011; Carroll, 2011).
Additionally, repair through nonhomologous end-joining
(NHEJ) can be exploited to create random single-base changes,
small insertions, or deletions. ZFNs enabled the generation of the
first targeted knockout rats at surprisingly high efficiency (Geurts
et al., 2009), and the technology of both ZFNs and TALENs
promises faster and more precise genomic manipulation or
‘‘genome editing’’ of virtually any organism, including plants,
worms, and other mammals (Hockemeyer et al., 2011; Miller
et al., 2011; Townsend et al., 2009; Wood et al., 2011). Still,
‘‘off-target effects’’ remain a significant concern for nuclease-
mediated therapies, as double-strand breaks induced outside
the target region can causemutations that are almost impossible
to detect without whole-genome analysis. Thorough sequencing
efforts will be required to define the true off-target ‘‘hit rate’’ of
each nuclease pair.
For those wanting to develop a mouse model targeting their
favorite gene, the options are faster and more flexible than
even 5 years ago. Through both commercial companies and
publicly funded repositories, tools for genome manipulation
have never been easier to access. As the catalog of mouse
knockouts grows and validated genome-wide shRNA and
ZFN/TALEN collections become a reality, the question is no
longer whether we can produce the mouse models but whether
we can leverage the power of each approach to develop models
that accurately recapitulate the simple or complex genetics of
human disease.
Managing the Multiallelic Nature of Human Disease
Generating multiallelic transgenic mouse models has facilitated
understanding of complex diseases. For example, it is clear
that the malignant endpoint arises as a combination of genetic
mutations. The order and nature of these changes impact
disease evolution, influencing which genes are required for
disease maintenance and hence encode suitable therapeutic
targets. More and more, genetic and genomic studies are high-
lighting the multifactorial nature of human disease, and it is likely
that as we unravel the complexities of this information, such
models will become increasingly important, not only as tools to
understand disease mechanisms but also as accurate models
for preclinical evaluation of potential therapies. Ignoring for
a moment the formidable task to produce and characterize
mutants, knockouts, and knockdowns of all known genes
(currently underway), the process of intercrossing these indi-
vidual alleles is even more tedious, time-consuming, and thus
expensive. This constant barrier severely limits the scale at
which complex genetic experiments can be performed and
thus the number of genetic combinations that can be examined
in vivo.
‘‘Speedy’’ ESC Models of Disease
To expedite the process of multiallelic mouse model production,
we and others have begun to develop so-called ‘‘chimeric-
GEMM’’ or ‘‘GEMM-ESC’’ models (Figure 2) (Huijbers et al.,
2011; Premsrirut et al., 2011; Zhou et al., 2010). This approach
is based on the derivation of ESCs carrying disease-associatedCell 148, March 16, 2012 ª2012 Elsevier Inc. 1101
alleles that in combination generate a functional mouse model of
disease. Like wild-type ESC lines, GEMM-ESCs can be manipu-
lated in vitro, through standard (homologous recombination)
targeting, using ZFNs/TALENs or through the introduction of
shRNAs/cDNAs by RMCE. In this way, many different genes
and genetic contexts can be interrogated in parallel. Generation
of chimeric or genetically identical mice (by blastocyst injection
or tetraploid complementation, respectively) facilitates the
production of large cohorts of experimental animals for analysis
and/or preclinical treatment studies. Moreover, animal produc-
tion does not rely on breeding success and thus can be tailored
to the needs of the user and synchronized for streamlined exper-
imental protocols.
We recently showed that rederived ESCs carrying four alleles
(LSL-KRasG12D, CCSP-rtTA, Rosa26-LSL-luciferase, and the
Col1A1-RMCE cassette) can be used to generate a mouse
model of lung adenocarcinoma in only a fraction of the time
required to develop and breed the genetic combinations through
traditional crossing (Premsrirut et al., 2011). Zhou et al. also
showed that similar results can be achieved through consecutive
rounds of ESC targeting and selection (Zhou et al., 2010). The
ultimate goal of such efforts is the creation of a diverse bank of
ESC models that could be accessed as needed to investigate
specific biological questions or triage a set of candidate genes
identified by patient sequencing or other screening approaches.
To date, ESC-based proof-of-principle studies have been
focused on the development of complex genetic combinations
for modeling cancer in the mouse, but similar methods can be
adapted to create GEMM-ESC models for any genetic disease.
For instance, Nichols et al. recently reported the generation of
germline-competent ESCs from the nonobese diabetic (NOD)
mouse strain—providing a platform for the rapid functional anal-
ysis of candidate diabetes modifiers (Nichols et al., 2009).
Similarly, GEMM-ESCs could be developed for complex trans-
genic strains such as the humanized sickle-cell disease mouse
(discussed later) or for models of muscular dystrophy (Sacco
et al., 2010) and cancer (Maser et al., 2007) that rely on multiple
generations of breeding on a telomerase-compromised back-
ground.
The GEMM-ESC approach promises a significant reduction in
the maintenance of large, expensive breeding colonies but more
importantly a dramatic increase in the throughput of functional
annotation of disease genes. Taking advantage of the vast array
of targeting vectors in public repositories and shRNA and ZFN/
TALEN technology, the possibility to create flexible, tailored,
and complex models of disease is incredibly exciting.
Mosaic Mouse Models
An alternative approach for recapitulating complex genetic
situations that is particularly relevant for cancer research is the
use of ‘‘mosaic’’ or ‘‘non-germline’’ mouse models. We and
others have used orthotopic transplantation-based mosaic
models in combination with viral delivery of cDNAs and shRNAs
to generate mouse models of a variety of cancers, including
leukemia, lymphoma, breast and pancreatic cancer, and hepato-
cellular carcinoma, among others (for review, see Heyer et al.,
2010). Similarly, some laboratories have successfully adapted
the avian virus RCAS-Tva system to deliver genes and shRNAs
that promote cancer in the adult mouse (Hambardzumyan1102 Cell 148, March 16, 2012 ª2012 Elsevier Inc.et al., 2009; Seidler et al., 2008). Recently, Beronja and Livshits
et al. described an approach for the efficient delivery of lentivirus
(carrying cDNAs and/or shRNAs) to the epidermis of developing
embryos, enabling widespread (almost complete) genetic
modification of the skin lineages without the need for cell trans-
plantation or germline transgenesis (Beronja et al., 2010).
All of these non-germline approaches share a common
theme—the flexibility to quickly alter the genetics of the target
cell and vary that of the host (microenvironment) to rapidly inter-
rogate the function of not just single genes but networks or whole
pathways. Together the methodologies provide an incredible
tool with which to dissect the genetic components of disease.
Improved orthotopic transplantation and/or delivery of genetic
material (e.g., Cre recombinase, shRNAs, reporters) to different
organ systems in vivo will open the door for the use of such
mosaic models in a wide range of disease research fields.
Together the evolving repositories and large-scale phenotyp-
ing efforts, ESC-GEMMs, andmosaicmodels provide an array of
tools to tackle what is an emerging challenge in biology: making
sense of the flood of information streaming out of GWAS, whole-
genome sequencing, and functional genomic screens to define
those variations that contribute most to human disease. Func-
tional studies are crucial for realizing the fruits of these large-
scale but descriptive efforts, yet traditional methods have been
too slow to interrogate more than a handful of variants. However,
with recent application of more high-throughput methods, it has
been possible to filter genomic data from human disease in
mouse models, finding genes that act as drivers of disease (Sa-
wey et al., 2011; Zender et al., 2008). When combined with
genome editing and shRNA technologies, these platforms will
provide a rapid means to mimic the many mutational and
gene-dosage alterations identified in human disease. Ultimately,
there will be no ‘‘one-size-fits-all’’ disease model, but increasing
accessibility to a range of refined experimental systems will play
a central role in ‘‘functionalizing’’ the human genome.
Forward Genetics to Tackle Complex Genomes
Identifying the genes that cause or contribute to disease is
a significant task, particularly when the disease is caused by
multiple genetic factors. Analysis of genomic information from
patients is one approach, although defining meaningful gene-
disease associations requires incredibly large datasets. Another,
unbiased approach that has been the mainstay of lower genetic
model systems is disease gene identification through forward
genetic screens.
N-ethyl-N-nitrosourea
Implementation of forward genetics in mice, historically through
N-ethyl-N-nitrosourea (ENU) mutagenesis (for review, see Kile
and Hilton, 2005), has been effective not only in generating
monoallelic mouse models of specific human diseases but also
in identifying modifiers and genetic interactions through ‘‘sensi-
tized’’ screens in models of diabetes, developmental neuropa-
thies, and disorders such as Waardenburg’s syndrome (Matera
et al., 2007; Stottmann et al., 2011; Tchekneva et al., 2007).
However, until recently, mapping disease-causative mutations
following ENU treatment was notoriously time consuming and
complex. Now, as the ‘‘$1000genome’’ is set to becomea reality,
‘‘next-generation’’ sequencing is revolutionizing the value and
Figure 2. Traditional and ‘‘Speedy’’ Mouse Model Development
The development of traditional knockout and conditional knockout mice requires the generation of unique targeting vectors, low-efficiency homologous
recombination, identification of founders that transmit the targeted allele through the germline, and subsequent breeding and/or backcrossing. ESC-based
GEMMs make use of multiallelic ESCs developed through multiple rounds of ESC targeting (chimeric-GEMMs) or rederivation of ESCs carrying established
disease alleles (speedy or GEMM-ESCs). The initial establishment phase of GEMM-ESCmodels demands breeding but, once created, requires little manipulation
in vitro. Experimental cohorts can be produced directly from the multiallele ESC and do not require any breeding steps. Experimental mice can be generated by
blastocyst injection, by producing chimeric mice (depicted by brown and white coat color), or through tetraploid embryo complementation, generating wholly
ESC-derived animals (brown coat).feasibility of large-scale forward genetic screens—and ENU
mutagenesis programs all over the world are taking full advan-
tage. For example, in recent years, laboratories at The Scripps
Research Institute (B. Beutler) and the Australian National
University (C. Goodnow) have generated and cataloged
hundreds of novel mutant strains (http://mutagenetix.scripps.
edu). An additional by-product of this effort has been the identi-
fication of more than 1,800 ‘‘incidental mutations,’’ foundthrough whole-genome sequencing, that offer a tremendous
potential resource for the research community. In concept,
sensitized ENU screens offer an ideal setting to interrogate the
mechanisms underlying complex genetic traits such as learning
and behavioral disorders (e.g., autism and schizophrenia),
cardiovascular disease, diabetes, and other autoimmune condi-
tions. With future decreased cost and increased throughput and
sensitivity of genome sequencing, effectively executing theseCell 148, March 16, 2012 ª2012 Elsevier Inc. 1103
types of comprehensive screens may no longer be the exclusive
domain of dedicated mouse-breeding consortia.
Transposons and shRNAs
For the discovery of genes involved in cancer, viral and trans-
poson mutagenesis and pooled cDNA and shRNA screens
have a proven history (Heyer et al., 2010; Kool and Berns,
2009). In recent years, the laboratories of Copeland/Jenkins,
Largaespada, and others have developed elegant transgenic
mouse strategies to activate highly mutagenic Sleeping Beauty
(SB) transposons in a temporal and tissue-specific manner
(reviewed in Copeland and Jenkins, 2010). Recently, SB tech-
nology has been effectively combined with tissue-specific
GEM models of intestinal cancer and melanoma to identify
genetic events that contribute to malignant progression (Karreth
et al., 2011; March et al., 2011; Starr et al., 2009). Moreover,
application of next-generation sequencing to deconvolute these
SB screens enables the identification of common insertion sites
and is sufficiently sensitive to reveal frequent co-occurrence of
insertion sites that may suggest cooperative interaction between
specific gene networks (March et al., 2011). It will be interesting
to see how the generation of more and more similar datasets will
inform our understanding of regulatory networks in disease.
Although the majority of SB integrations result in gain-of-func-
tion activity in nearby genes (overexpression), the system, in
theory, provides an unbiased approach for identification of any
cancer-relevant genetic event. In contrast, cDNA/shRNA
screens can be configured to be broad (genome-wide), narrow
(directed at a particular pathway or process), or, as has recently
proven fruitful, guided by human genomic data (Sawey et al.,
2011; Scott et al., 2011; Zender et al., 2008). Our lab and others
have used a variety of non-germline mosaic models and cancer-
focused shRNA libraries as a screening platform in both
lymphoma and hepatocellular carcinoma models to identify
numerous novel tumor suppressor genes (for review, see Heyer
et al., 2010). Similarly, screening libraries of cDNAs recurrently
amplified in human tumors has yielded insights into the biology
of malignant progression (Sawey et al., 2011; Scott et al.,
2011). The development of large cDNA and shRNA repositories
(e.g., Open Biosystems) in the past 5 years has significantly
increased the feasibility of these screening approaches for
most labs, and continued improvements in organ-directed viral
and transposase gene/shRNA delivery to adult mice will further
fuel the use of mosaicmodels as a gene discovery tool in disease
research. Together these approaches will identify new cancer
drivers and also better model the genetic heterogeneity of
cancer that occurs in human patients.
Finding the Weakest Link—Drug Target Discovery
and Validation
Understanding the factors that are essential for disease progres-
sion and maintenance is key to developing effective treatment
strategies. As more information concerning the underlying
genetic basis of disease is produced, as well as modifiers of
disease penetrance and progression, efforts to consider more
personalized therapies are becoming attractive. Although only
clinical trials with a drug can truly validate its efficacy in disease
treatment, model systems can be highly useful in drug target
discovery owing to the ability to precisely control the genetic
background and/or in vivo microenvironment. Indeed, traditional1104 Cell 148, March 16, 2012 ª2012 Elsevier Inc.knockout mice have been used to assess the consequences of
target inhibition in vivo but suffer from the disadvantage that
gene deletions examine disease initiation and not maintenance,
whereas conditional gene deletion in established disease is often
inefficient and cannot mimic a transient treatment regime, as it
is not reversible. Moreover, such approaches are sufficiently
slow and expensive to allow for interrogation of only one or, at
most, a few targets.
Most current drugs act as inhibitors of protein function. As
such, inducible RNAi provides an effective tool to interrogate
the potential consequences of protein silencing in established
disease and, better, can be applied on a high-throughput scale
(Zuber et al., 2011a). Indeed, in vivo screens to identify genes
that modulate cell survival or drug response have been reported,
some leading to unanticipated therapeutic strategies, for
example, the utilities of Brd4 inhibitors to treat aggressive forms
of acute myeloid leukemia (AML) (Zuber et al., 2011b). Similar
in vivo screening strategies have been used to identify compo-
nents of the actin machinery and metabolome as key regulators
of disease maintenance in lymphoma and breast cancer,
respectively (Meacham et al., 2009; Possemato et al., 2011).
Even for screens performed in vitro, in vivo validation with induc-
ible shRNA systems, such as GEMM-ESC models, is a fast and
powerful check that an identified gene/pathway is indeed a valid
target. Currently most studies require an in vitro step and trans-
plantation into conditioned recipients; however, improved viral
and transposon-baseddeliverymayultimately enable truly in vivo
screens, most likely to capture the precise conditions in which
a therapy should be efficacious. Integrating these approaches
provides a powerful means for vetting potential therapeutic
targets before investing in expensive drug development
projects.
Mouse models may be an effective system for drug target
discovery, but whether they represent an ideal platform for eval-
uating potential drug intervention strategies has been a more
controversial topic. Historically, drug regimens established in
mouse models of various diseases have shown mixed perfor-
mance in clinical settings (Driver et al., 2011; Olive et al., 2009;
Richmond and Su, 2008; Talmadge et al., 2007). Although this
signaled to many that mouse models were not appropriate
predictive systems, it may reflect technical limitations of those
systems rather than the usefulness of the mouse for drug inter-
vention trials. In the past few years, the development of more
sophisticated transgenic models, better humanized mice (dis-
cussed below), and powerful small animal imaging platforms
has shown that the mouse can be an effective gateway for trans-
lational research. Importantly, some models can accurately
mimic the response and resistance observed in the clinic (Zhou
et al., 2010), although models that predict drug-induced relapse
have been limited thus far. Additionally, inducible and reversible
shRNA mouse models now offer a setting to genetically test the
effect of reactivating suppressed gene networks or inhibiting
potential drug targets. Notwithstanding the important differ-
ences between mice and humans in terms of drug specificity
and metabolism, with the increased arsenal of genetic tools,
the mouse represents arguably the most flexible system to filter
drug candidates before entering enormously expensive clinical
trials.
As we move forward with functional annotation of the disease
genome, describing the complex genetic interactions that
contribute to biological dysfunction will be a challenging
process. An important tool will be the integration of technologies
to pinpoint disease genes, such as using genomic data to inform
the genesis of targeted mouse models and gene sets for forward
genetic screens. In addition, continual advances in sequencing
technology are driving forward both genome resequencing and
mutagenesis screens at an unprecedented scale. Intersecting
and cross-referencing the results from these approaches will
surely identify high-confidence ‘‘hits’’ that can then be rapidly
moved into relevant hypothesis-driven preclinical models.
Moving beyond the Mouse: When Size Does Matter
Although the rat is often overshadowed by its smaller cousin,
many researchers turn to it in settings where physiological or
anatomical restrictions limit the utility of the mouse. In fact,
although genetic tools and ESC manipulations are significantly
more sophisticated in the mouse, rats as a model system have
many advantages over mice: they have more similar cardiovas-
cular and respiratory physiology (heart and breath rate is signif-
icantly slower than the mouse), are considered smarter and thus
better for learning and addiction research, and are the preferred
preclinical rodent model for drug toxicity evaluation. In addition,
their larger size (around ten times that of mice) enables more
frequent blood sampling, easier measurement of biometric
parameters such as blood pressure, and more straightforward
imaging of brain activity for neuronal research.
Paralleling the early days of mouse genetics, disease models
in the rat have relied heavily on spontaneous or chemically
derived (ENU) mutants. Two spontaneously derived models,
the type 1 diabetes-prone BB rat and the spontaneous hyperten-
sive rat, were identified over 30 years ago and remain two of the
most heavily used models systems for understanding human
metabolic and cardiovascular disease (Mordes et al., 2004; Pinto
et al., 1998). Even in cancer research, the traditional domain of
the mouse, rats have also proven useful. As one example,
Dove and colleagues recently identified an ENU-induced mutant
rat strain (pirc) that carries a missense mutation in the adenoma-
tous polyposis coli (APC) gene (Amos-Landgraf et al., 2007)
similar to those described in mouse models and patients with
familial adenomatous polyposis (FAP). However, in contrast to
the mouse, which develops polyps almost exclusively in the
intestine, the pirc rat kindred shows a greater burden of polyps
in the colon, which is more similar to human FAP. This important
distinction also provide a means to monitor tumor growth and
response to therapies via colonoscopy, something more chal-
lenging in the smaller mouse organ and impossible for tumors
that arise in the intestine.
Despite their utility for disease research, rat models have been
limited by a lack of tools to manipulate the genome. However,
recent advances in rat ESC culture and nuclease-driven genetic
manipulation of rat genomes have now opened the door for more
advanced genetic models. In 2008, two groups reported the
derivation of the first germline-competent rat ESCs from two
different inbred strains (Buehr et al., 2008; Li et al., 2008), and
subsequently, Ying and colleagues described the generation of
a p53 null rat with the same homologous recombinationapproach that produced the original p53 null mouse 20 years
earlier (Tong et al., 2010). The long sought after establishment
of rat ESCs through advances in culture conditions also
suggests that other, potentially relevant mammalian models
could be adapted for the same types of systematic genetic engi-
neering that are currently being accomplished in the mouse.
The second major advance for rat came in 2009 when Guerts
et al. used ZFNs to create targeted knockout rats without the
need for ESC culture (Geurts et al., 2009). Since that time,
many more knockout/mutant strains have been produced, and
efforts are currently underway to develop 100 new rat models
of hypertension and kidney disease (Dolgin, 2010). In addition,
Tesson et al. have reported the use of TALENs to generate
knockout rats, adding another tool to the rat geneticist armory
(Tesson et al., 2011). Some commercial entities are now also
offering custom production of ZFN-derived mutant rats and
doxycycline-regulated shRNA transgenic rats—albeit at a signif-
icant cost. Given the preference for the larger rodents as
a system to evaluate drug efficacy, it is likely that many of these
genetically engineered rats will replacemice as front-line preclin-
ical models. However, their (significant) housing costs make it
unlikely that rats will supersede the mouse as a workhorse
genetic tool in academic research.
A Man or a Mouse?
Species-specific problems with rodent-based research, be they
genetic or physiological, will only be overcome by conducting
experiments on human cells. Xenograft-based human tumor
experiments in immunocompromised host mice have for many
years served as a surrogate for tumorigenicity and preclinical
modeling. However, as more evidence mounts for the impor-
tance of immune cell interaction and the tumor microenviron-
ment, these models are quickly losing favor. Moreover, there
are hundreds of diseases besides cancer—such as metabolic
and autoimmune disorders and bacterial and viral infectious
diseases—that would benefit from direct examination of human
tissues.
Humanized Mice
The term ‘‘humanized mice’’ describes both the expression of
a human gene or genes in a transgenic context and/or the
engraftment of immunocompromised mice with human immune
cells. A number of model systems have been developed, based
on the expression of disease-specific human alleles. The best
example of this is the replacement of mouse globin genes with
their human counterparts (including both wild-type and sickle-
cell disease [SCD] mutant b-globins) to recreate the disease
progression of human SCD. This humanized mouse, now avail-
able through the Jax repository, has been essential for evaluating
new autologous gene therapy approaches and small-molecule-
based treatments for SCD (Chang et al., 2010; Hanna et al.,
2007).
The creation of humanized models through engraftment of
CD34+ human hematopoetic stem cells (hHSCs) or peripheral
blood mononucleocytes (PBMCs) has recently expanded,
following the development of severely immunocompromised
strains that act as optimal recipients for human stem cells, in
particular the NOD-severe combined immunodeficiency
(SCID)-Il2rg/ (NSG) mice (McDermott et al., 2010). SuchCell 148, March 16, 2012 ª2012 Elsevier Inc. 1105
mice have proven invaluable for understanding the normal func-
tion of the human immune system as well as the (human)
response to viral and microbial pathogens, such as hepatitis C
virus and HIV, that do not infect mouse tissues (Shultz et al.,
2007). In some cases, humanized models have also shown effi-
cacy for the development and testing of vaccines (Yu et al.,
2008).
Mice humanized by the ectopic expression of human cyto-
kines show improved grafting of hHSCs and the development
of more sustained natural killer (NK) and myeloid cell responses
(Billerbeck et al., 2011; Chen et al., 2009) presumably by
providing more effective crosstalk between mouse and human
compartments. In addition, scientists at the Jackson Laborato-
ries have reported that NSG mice expressing human HLA mole-
cules not only provide a good setting for hHSCs engraftment but
also allow a stronger antigen-dependent T cell response than
current models (Shultz et al., 2010). The progressive advances
of ‘‘humanizing’’ technology suggest that with the right combina-
tion of factors (in both the host and donor tissue), NSG-based
humanized models will provide the best surrogate for human
immune studies. However, the reproducible generation of
humanized chimeras is technically challenging and, for most
labs, not yet cost effective for the production of large cohorts
for high-throughput studies.
Reprogramming Human Cell Models
Five years ago, Yamanaka and colleagues reported their seminal
discovery that mouse (2006) and human (2007) fibroblasts could
be ‘‘reprogrammed’’ (by viral delivery of four transcription
factors:Oct4,Sox2,Klf4, and c-Myc) to a state of induced plurip-
otency, capable of generating all somatic cell types (Takahashi
et al., 2007; Takahashi and Yamanaka, 2006). These observa-
tions led to the first platform to produce and study nonembryonic
and nontransformed human cells. Driven by the hope of autolo-
gous gene therapy and regenerative medicine, induced pluripo-
tent stem cell (iPSC) technology has evolved extensively (for
review, see Stadtfeld and Hochedlinger, 2010). It is now possible
to generate human iPSCs with only modified mRNA transcripts
or purified proteins (Kim et al., 2009; Warren et al., 2010; Zhou
et al., 2009), eliminating the need for disruption of the host
genome by viral or plasmid transgenesis and providing ‘‘clean’’
reprogrammed cells for functional analysis.
The implications of iPSC technology for disease research and
treatment are profound. The generation of patient-specific
iPSCs provides a previously unimagined avenue for the dissec-
tion of simple and complex genetic diseases, with almost
limitless access to sample. Already, a number of groups have
reported the development of patient-specific iPSCs for diverse
monogenic disorders such as Long-QT syndrome, SCD,
Lesch-Nyan syndrome, and retinitis pigmentosis and complex
traits such as Parkinson’s disease and schizophrenia (Brennand
et al., 2011; Jin et al., 2011; Moretti et al., 2010; Soldner et al.,
2009; Zou et al., 2011). Importantly, in many of these cases the
iPSC clones can be reproducibly differentiated into the cell types
in which the disease manifests.
iPSCs are also being used as a therapeutic tool. For example,
Rhee et al. recently showed that human iPSC-derived neurons
rescue motor deficits when transplanted into a rat model of
Parkinson’s disease (Rhee et al., 2011), implying that in vitro1106 Cell 148, March 16, 2012 ª2012 Elsevier Inc.differentiation can produce fully functional cell populations.
Further, disease-specific differentiated cell types can show pre-
dicted phenotypic traits and response to disease-relevant drugs
in vitro (Brennand et al., 2011), suggesting that in some cases an
in vivo animal system may not be a requisite for disease
research. All the early iPSC data look genuinely promising,
although most of the successful examples reported thus far
have used protocols to differentiate iPSCs into a restricted
number of cell types, commonly neurons and cardiac myocytes.
The development of standardized protocols for the reproducible
derivation of diverse cell types in vitro will be key to harnessing
the power of iPSC-based disease models.
The creation of large repositories of disease and ‘‘normal’’
iPSCs will eventually open the door for large-scale functional
genetics with shRNA libraries and high-throughput drug sensi-
tivity/toxicity screens, much as is occurring now in cell lines
and engineered mice. For cancer studies, production of new
tumor cell lines frombiopsies could be paralleled by the develop-
ment of patient-specific fibroblast iPSC lines that would serve as
a matched ‘‘normal’’ tissue for functional studies and large-scale
drug and shRNA-negative selection screens. Such screens not
only will enable dissection of the genetic requirements of disease
but could identify potential therapeutic avenues for individual-
ized disease management. Some have also suggested that
iPSCs could one day provide a useful surrogate for testing
patient-specific response and drug toxicity prior to clinical treat-
ment, although the protocols for iPSC derivation and differentia-
tion are currently too slow for this to become a reality.
iPSCs and Genome Editing in the Clinic
One of the most exciting possibilities of patient-specific iPSC
technology is the potential for autologous cell therapy with
‘‘gene-corrected’’ patient cells. The ability to selectively alter
the genome of iPSCs would also strengthen the value of iPSCs
as a models system, allowing the controlled perturbation of
gene function or ‘‘correction’’ of disease-specific mutations in
human cells. In this regard, the continued development and
application of sequence-specific nucleases such as ZFNs and
TALENs provides one path toward achieving this goal.
In the past 2 years, numerous groups have demonstrated the
potential for targeted nucleases in genome editing and transla-
tional research for human disease, including the correction of
mutations causing SCD and the autosomal recessive metabolic
disorder a1-antitrypsin deficiency (A1ATD) in iPSCs (Sebastiano
et al., 2011; Yusa et al., 2011; Zou et al., 2011). Perhaps the
most exciting of these results are data from a humanized mouse
model carrying HIV, which show that disruption of the HIV core-
ceptor CCR5 with ZFNs could generate resistance to viral infec-
tion (Holt et al., 2010; Perez et al., 2008). Early positive signs from
phase I clinical trials suggest that this formof genomeeditingmay
become a true success story of translational research, although
for reasons mentioned above, concerns linger for the potential
mutagenicity of such an approach. For additional discussion on
iPSCs in the study of human diseases, please see Perspective
by Cherry and Daley on page 1110 of this issue.
Getting a Move On: Looking to the Future
Over the past two decades, the development of new model sys-
tems to recapitulate and study human disease has progressed at
an astonishing rate. A variety of approaches and methodologies
have been adapted to manipulate the genomes of mouse, rat,
and human cells and thus enable systematic analysis of the
genetic requirements of disease initiation and maintenance.
The present challenge for the biomedical research community
is two-fold: (1) integrate the large array of sophisticated genetic
tools to produce the best and most predictive model system or
systems to define treatment strategies, and (2) develop these
models at a rate so as to accommodate testing and/or validation
of the many candidate disease genes being identified by micro-
array/ChIPseq/CGH, shRNA and mutagenesis screens, and
GWAS. Already, the development of platforms to quickly
produce ESC or iPSC-based models shows how interrogation
and understanding of disease progression need not be a slow
process. With this increased efficiency, the mechanisms under-
lying disease pathogenesis can now be investigated in a variety
of different settings, providing the best chance of finding effec-
tive therapeutic avenues in the shortest time possible.
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